Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DR-2011 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DR-2011 | DRUG | Progesterone vaginal ring for approximately 10 weeks |
| Crinone 8% | DRUG | progesterone vaginal gel for approximately 10 weeks |
| Progesterone 8% Vaginal Gel | DRUG | Administered vaginally from Cycle Day 14 to Day 31 |
Inclusion Criteria: * Pre-menopausal, aged 18-42 old at time of consent * At least one cycle without fertility medication prior to screening * Tubal, idiopathic, male factor, ovulatory dysfunction or endometriosis- linked infertility * Semen analysis (frozen sperm, including donor sperm, may be use...
DR-2011 is an investigational small molecule being developed for infertility. It is being studied for luteal phase replacement and for use in in vitro fertilization. The drug is currently in Phase 3 clinical development and is not approved by the FDA.
DR-2011 is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting clinical trials to evaluate the drug's efficacy and safety for infertility treatment.
DR-2011 is in Phase 3 clinical development. It has completed two clinical trials, including a Phase 3 study with 1,297 participants. The drug is investigational and has not received FDA approval.
DR-2011 has completed two clinical trials. NCT00117468 was a Phase 2 study comparing DR-2011 to a progesterone vaginal gel for luteal phase replacement, enrolling 20 participants. NCT00615251 was a Phase 3 trial evaluating DR-2011 for in vitro fertilization, enrolling 1,297 participants.
DR-2011 is a small molecule being studied for infertility. The specific molecular target of DR-2011 has not been disclosed in the available clinical trial information.